Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumococcal Vaccines | 10 | 2025 | 278 | 1.420 |
Why?
|
| Immunization Schedule | 12 | 2025 | 81 | 1.390 |
Why?
|
| Immunogenicity, Vaccine | 12 | 2025 | 103 | 1.200 |
Why?
|
| Antibodies, Bacterial | 11 | 2025 | 153 | 1.030 |
Why?
|
| Pneumococcal Infections | 9 | 2025 | 299 | 0.980 |
Why?
|
| Immunization, Secondary | 8 | 2025 | 72 | 0.950 |
Why?
|
| Antibodies, Viral | 13 | 2024 | 284 | 0.920 |
Why?
|
| Haemophilus Vaccines | 3 | 2020 | 41 | 0.850 |
Why?
|
| Infant | 25 | 2025 | 2244 | 0.770 |
Why?
|
| HIV Infections | 14 | 2024 | 5097 | 0.750 |
Why?
|
| Streptococcus pneumoniae | 5 | 2025 | 336 | 0.680 |
Why?
|
| Vaccination | 10 | 2024 | 365 | 0.680 |
Why?
|
| Immunoglobulin G | 12 | 2025 | 231 | 0.660 |
Why?
|
| Humans | 38 | 2025 | 14537 | 0.600 |
Why?
|
| Antibodies, Neutralizing | 8 | 2024 | 303 | 0.590 |
Why?
|
| Rotavirus Vaccines | 4 | 2021 | 53 | 0.580 |
Why?
|
| South Africa | 27 | 2025 | 7596 | 0.570 |
Why?
|
| Vaccines | 3 | 2023 | 86 | 0.560 |
Why?
|
| Vaccines, Conjugate | 7 | 2025 | 171 | 0.480 |
Why?
|
| Nasopharynx | 4 | 2024 | 151 | 0.460 |
Why?
|
| Serogroup | 2 | 2025 | 150 | 0.450 |
Why?
|
| Measles Vaccine | 2 | 2024 | 34 | 0.390 |
Why?
|
| Rotavirus | 3 | 2021 | 29 | 0.380 |
Why?
|
| Streptococcus agalactiae | 4 | 2017 | 202 | 0.370 |
Why?
|
| Adult | 15 | 2024 | 5913 | 0.370 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 200 | 0.360 |
Why?
|
| Vaccines, Combined | 3 | 2020 | 34 | 0.350 |
Why?
|
| Immunity, Maternally-Acquired | 4 | 2020 | 40 | 0.340 |
Why?
|
| Female | 21 | 2025 | 9103 | 0.340 |
Why?
|
| Carrier State | 3 | 2024 | 92 | 0.330 |
Why?
|
| Male | 17 | 2025 | 6754 | 0.330 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2020 | 28 | 0.320 |
Why?
|
| Double-Blind Method | 8 | 2022 | 272 | 0.320 |
Why?
|
| Child, Preschool | 9 | 2024 | 1748 | 0.290 |
Why?
|
| Chickenpox Vaccine | 2 | 2020 | 6 | 0.280 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 101 | 0.270 |
Why?
|
| Streptococcal Infections | 3 | 2016 | 184 | 0.240 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 34 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 77 | 0.220 |
Why?
|
| Nutritional Status | 1 | 2024 | 76 | 0.220 |
Why?
|
| Child | 4 | 2023 | 2242 | 0.210 |
Why?
|
| Haemophilus influenzae | 2 | 2020 | 42 | 0.210 |
Why?
|
| Vaccines, Subunit | 2 | 2020 | 8 | 0.210 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2020 | 17 | 0.210 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2020 | 11 | 0.210 |
Why?
|
| Hepatitis B Vaccines | 2 | 2020 | 40 | 0.200 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 4 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2024 | 1160 | 0.200 |
Why?
|
| Antibody Formation | 3 | 2021 | 61 | 0.200 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2021 | 2 | 0.190 |
Why?
|
| Young Adult | 7 | 2024 | 2498 | 0.190 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 155 | 0.180 |
Why?
|
| Pregnancy | 4 | 2020 | 1862 | 0.180 |
Why?
|
| Adolescent | 7 | 2024 | 2985 | 0.180 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2020 | 42 | 0.180 |
Why?
|
| Isoantibodies | 1 | 2020 | 15 | 0.170 |
Why?
|
| Hepatitis A Vaccines | 1 | 2020 | 2 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2020 | 49 | 0.170 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 52 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 266 | 0.170 |
Why?
|
| HLA Antigens | 1 | 2020 | 50 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 119 | 0.170 |
Why?
|
| Maternal Exposure | 1 | 2019 | 14 | 0.170 |
Why?
|
| Measles | 1 | 2019 | 36 | 0.160 |
Why?
|
| Streptococcal Vaccines | 2 | 2016 | 47 | 0.160 |
Why?
|
| Middle Aged | 6 | 2024 | 3601 | 0.150 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2017 | 15 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2022 | 543 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 889 | 0.120 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 73 | 0.120 |
Why?
|
| Immunoglobulin A | 3 | 2023 | 39 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2022 | 1479 | 0.110 |
Why?
|
| Milk, Human | 1 | 2014 | 23 | 0.110 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Tetanus Toxoid | 1 | 2013 | 14 | 0.110 |
Why?
|
| Rotavirus Infections | 1 | 2014 | 46 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2014 | 120 | 0.100 |
Why?
|
| Aged | 3 | 2024 | 1740 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 65 | 0.100 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 31 | 0.090 |
Why?
|
| Influenza B virus | 1 | 2011 | 42 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 54 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2020 | 17 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 144 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 34 | 0.080 |
Why?
|
| Immunization | 2 | 2020 | 63 | 0.070 |
Why?
|
| Vaccines, Attenuated | 2 | 2020 | 28 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 150 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2011 | 374 | 0.070 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 12 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2024 | 31 | 0.060 |
Why?
|
| Placebos | 2 | 2017 | 44 | 0.060 |
Why?
|
| Ghrelin | 1 | 2024 | 2 | 0.060 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 3 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 34 | 0.060 |
Why?
|
| Leptin | 1 | 2024 | 26 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2024 | 111 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 25 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 42 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2022 | 39 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2022 | 20 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 48 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 48 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 33 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 34 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 43 | 0.040 |
Why?
|
| Placental Circulation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2020 | 18 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 22 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2020 | 3 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 418 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 244 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 306 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
| United States | 1 | 2020 | 132 | 0.040 |
Why?
|
| Risk Factors | 2 | 2015 | 1475 | 0.040 |
Why?
|
| Kinetics | 1 | 2017 | 65 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2017 | 45 | 0.040 |
Why?
|
| Immunoglobulin D | 1 | 2017 | 4 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2017 | 13 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1192 | 0.030 |
Why?
|
| HIV-1 | 1 | 2024 | 1260 | 0.030 |
Why?
|
| Mothers | 1 | 2017 | 195 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 376 | 0.030 |
Why?
|
| Immunogenetic Phenomena | 1 | 2014 | 7 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2014 | 22 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 127 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 656 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 480 | 0.030 |
Why?
|
| Child Day Care Centers | 1 | 2013 | 4 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 325 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 45 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 685 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2013 | 135 | 0.030 |
Why?
|
| HIV | 1 | 2015 | 380 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 370 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 507 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 9 | 0.020 |
Why?
|
| Oropharynx | 1 | 2011 | 17 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 23 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 23 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 77 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2013 | 799 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 303 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 472 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 1324 | 0.010 |
Why?
|